Elena Nikulina

Biogen unveils real-world data on early Alzheimer treatment persistence in U.S.

Biogen unveils real-world data on early Alzheimer treatment persistence in U.S.
Biogen shares Alzheimer data

Biogen, in partnership with Eisai, has released new real-world data at the ADPD2026 conference examining long-term treatment persistence for people living with early Alzheimer disease in the U.S.

The data aims to shed light on how patients are maintaining therapy over extended periods, focusing on real-world applications rather than clinical trials alone. The findings are expected to inform future strategies for managing Alzheimer disease in its early stages.

The latest Alzheimer disease data from Biogen and Eisai builds on a series of pivotal research disclosures from the company, including recent advances in spinal muscular atrophy highlighted at the 2026 MDA Conference. Furthermore, the firm's earlier presentation of Phase 1b results for an investigational SMA treatment underscores Biogen’s continued focus on neurological disorders and its commitment to expanding real-world evidence across therapeutic areas.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.